Multicenter, Non-interventional Observational Prospective Study With Retrospective Analysis to Describe the Rate of CKD Diagnosis, in Patients With Arterial Hypertension and CKD Markers

Status: Recruiting
Location: See all (30) locations...
Study Type: Observational
SUMMARY

This study is a multi-centre, non-interventional, observational, prospective study with retrospective analysis. The main purpose of the study is to describe the rate of CKD diagnosis in patients with AH and CKD markers. This study will include 10 000 adult outpatients with arterial hypertension, who have one or more Chronic Kidney Disease laboratory markers (without recorded CKD diagnosis prior to enrolment) and have no diabetes mellitus or symptomatic chronic heart failure, who are monitored and treated by cardiologists or internal medicine specialists in approximately 50 outpatient sites in about 20 regions in Russia. This observational study does not provide for any diagnostic and therapeutic procedures other than those used in routine practice.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Male or female participants aged 18 years or older at the time of signing the ICF;

• Signed and dated written informed consent in accordance with ICH GCP and local law prior to inclusion in the study;

• Diagnosis of AH (essential hypertension) previously established in accordance with current Russian Clinical guidelines on arterial hypertension in adults, i.e. office systolic blood pressure (SBP) ≥140 mmHg and/or diastolic blood pressure (DBP) ≥90 mmHg, measured on two different visits;

• Laboratory markers of CKD (eGFR \< 60 ml/min/1,73 m2 and/or albuminuria/proteinuria\*), measured for the period of ≤12 months prior to enrolment. \*any of the following: urine ACR (albumin/creatinine ratio) ≥ 30 mg/g (3 mg/mmol), urine PCR (protein/creatinine ratio) ≥150 mg/g (15 mg/mmol), 24-h albuminuria ≥30 mg/day or 24-h proteinuria ≥ 0.15 g/day.

• No CKD diagnosis recorded in a patient's medical documents prior to enrollment

Locations
Other Locations
Russian Federation
Research Site
RECRUITING
Aramil
Research Site
RECRUITING
Chelyabinsk
Research Site
RECRUITING
Irkutsk
Research Site
RECRUITING
Kaluga
Research Site
RECRUITING
Kazan'
Research Site
RECRUITING
Kemerovo
Research Site
RECRUITING
Krasnodar
Research Site
RECRUITING
Krasnoyarsk
Research Site
RECRUITING
Moscow
Research Site
COMPLETED
Nizhny Novgorod
Research Site
RECRUITING
Novosibirsk
Research Site
RECRUITING
Odintsovo
Research Site
RECRUITING
Omsk
Research Site
RECRUITING
Penza
Research Site
RECRUITING
Perm
Research Site
RECRUITING
Reutov
Research Site
RECRUITING
Rostov-on-don
Research Site
RECRUITING
Ryazan
Research Site
RECRUITING
Saint Petersburg
Research Site
RECRUITING
Samara
Research Site
RECRUITING
Stavropol
Research Site
RECRUITING
Tomsk
Research Site
RECRUITING
Tula
Research Site
RECRUITING
Ufa
Research Site
RECRUITING
Ulan-ude
Research Site
RECRUITING
Volgograd
Research Site
RECRUITING
Vologda
Research Site
RECRUITING
Voronezh
Research Site
RECRUITING
Yaroslavl
Research Site
RECRUITING
Yekaterinburg
Contact Information
Primary
AstraZeneca Clinical Study Information Center
information.center@astrazeneca.com
1-877-240-9479
Time Frame
Start Date: 2024-01-15
Estimated Completion Date: 2025-10-31
Participants
Target number of participants: 10000
Related Therapeutic Areas
Sponsors
Leads: AstraZeneca

This content was sourced from clinicaltrials.gov